The medical journal Prescrire announced Friday that the anti-obesity pill Alli has not been marketed since 2012 in France. The GlaxoSmithKline Laboratory had a problem with the supply of the molecule in January 2012 and decided not to relaunch marketing in France. The National Medicines Safety Agency (ASNM) had reported the adverse effects of this medicine.
Alli, the anti-obesity drug from the British laboratory GlaxoSmithKline (GSK), which had been marketed in France since
2009, finally disappeared from the shelves… since 2012. The information, which was for the moment
gone unnoticed, was made public by the independent medical journal Prescribe and confirmed by the manufacturer.
The pill has been withdrawn from sale in France by GSK but it is however still on sale in most other European countries, as well as in the United States.
This anti-obesity pill was in the crosshairs of the National Security Agency
medicine (ANSM), which had reported in 2011 a “risk of harm
rare but serious hepatic ” presented by this treatment. The agency then had
placed Alli on its watch list.
Among the undesirable effects, we find intestinal disorders linked to the elimination of fats in the blood, anxiety, and in certain exceptional cases, pancreatitis or liver problems.
No more effective than a placebo
Alli contains 60 mg of orlistat, a component
which prevents the absorption of fats from the human diet.
According to the review Prescribe the effectiveness of this treatment is limited:
taking the Alli pill, patients could lose only 3.5 pounds more
than with a placebo, after 12 to 24 months.
In March 2012, the European Medicines Agency (EMA) affirmed that the benefit-risk ratio of orlistat, the component of Alli, remained favorable to patients in the treatment of overweight, when combined with a diet. eating.
Xenical, a drug produced by the Roche laboratory and
which contains 120mg of orlistat, remains marketed in France. He is not himself
available only on prescription.